<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03014167</url>
  </required_header>
  <id_info>
    <org_study_id>DeWorm3 Project</org_study_id>
    <nct_id>NCT03014167</nct_id>
  </id_info>
  <brief_title>Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)</brief_title>
  <official_title>Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natural History Museum, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche Clinique du Bénin (IRCB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christian Medical College, Vellore, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blantyre Institute for Community Ophthalmology (BICO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Natural History Museum, United Kingdom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 1.5 billion people are infected with soil-transmitted helminths (STH). Global STH
      guidelines recommend MDA (mass drug administration) of albendazole or mebendazole to targeted
      populations, including pre-school age children and school-age children. However mathematical
      models suggests that current MDA strategies are not sufficient for interrupting disease
      transmission in most areas. Meanwhile many lymphatic filariasis (LF) programs have
      successfully treated entire populations with albendazole (in combination with ivermectin or
      diethylcarbamazine) and are transitioning to a state of post-MDA surveillance. This project
      will conduct a series of community-based cluster randomized trials in India, Malawi, and
      Benin to determine if maintaining three years of MDA with albendazole to entire communities
      following the cessation of LF programs can interrupt STH transmission in focal geographic
      areas. Additionally, this study aims to compare the efficacy of community-wide MDA versus
      targeted MDA of children in interrupting the transmission of STH. Nested implementation
      science research will be used to optimize the intervention, identify contextual factors
      influencing trial efficacy, and evaluate the feasibility of sustaining and scaling
      community-wide MDA for STH. These data will provide evidence necessary to inform future
      guidelines, policies, and operational plans as country partners engage in intensified
      approaches to eliminate these disabling diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>STH transmission interruption</measure>
    <time_frame>5 years (Three years of drug administration and two years of surveillance)</time_frame>
    <description>Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240000</enrollment>
  <condition>Helminthiasis</condition>
  <condition>Filariasis</condition>
  <arm_group>
    <arm_group_label>Community-wide deworming</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Targeted deworming</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>All eligible individuals will receive a single dose of 400 mg albendazole.</description>
    <arm_group_label>Community-wide deworming</arm_group_label>
    <arm_group_label>Targeted deworming</arm_group_label>
    <other_name>Albenza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Treatment Inclusion Criteria:

          -  Ages 12 months and older

        Treatment Exclusion Criteria:

          -  Children under 12 months of age

          -  Pregnant women in their first trimester

          -  History of adverse reaction to benzimidazoles

        Outcome Sampling Inclusion Criteria:

          -  Resident of study clusters

          -  Ages 12 months and older

          -  Willingness of adult aged 18 years and above (or age as per country specific ethical
             guidelines) or parent/guardian of child to provide written informed consent

          -  Provision of written assent to participate from children aged 8 years and above (or
             age as per country specific ethical guidelines)

        Outcome Sampling Exclusion Criteria:

          -  Less than 12 months of age

          -  Individuals who do not typically reside in the study cluster

          -  Nonconsenting or assenting individuals, as applicable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judd L Walson, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington Department of Global Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judd L Walson, MD, MPH</last_name>
    <phone>206-744-3695</phone>
    <phone_ext>43695</phone_ext>
    <email>walson@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Recherche pour le Développement</name>
      <address>
        <city>Comé</city>
        <country>Benin</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Luty, PhD, DR</last_name>
      <email>adrian.luty@ird.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gagandeep Kang, MBBS, MD, PhD</last_name>
      <email>gkang@cmcvellore.ac.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London School of Hygiene and Tropical Medicine</name>
      <address>
        <city>Mangochi</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Bailey, MA, BM, MRCP, DTM&amp;H, PhD, FRCP</last_name>
      <email>robin.bailey@lshtm.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>India</country>
    <country>Malawi</country>
  </location_countries>
  <link>
    <url>http://www.nhm.ac.uk/our-science/our-work/sustainability/deworm3.html</url>
    <description>Natural History Museum DeWorm3 Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transmission interruption</keyword>
  <keyword>intestinal nematodes</keyword>
  <keyword>soil-transmitted helminths</keyword>
  <keyword>mass drug administration</keyword>
  <keyword>Benin</keyword>
  <keyword>India</keyword>
  <keyword>Malawi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Helminthiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

